Assessment of the effects of gastric degradation-protected pea protein extract on mucosal satiety hormone release by human duodenal tissue

Assessment of the effects of gastric degradation-protected pea protein extract on mucosal satiety hormone release by human duodenal tissue - Protected pea protein extract and satiety hormone release

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON38483

Enrollment

Registered

2013-02-20

Start date

2013-02-25

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesitas Obesity overweight

Interventions

Participants will have to visit the study site once. For the gastric fluid experiment the participant will receive a nasogastric catheter and about 75 mL gastric fluid will be aspirated. On another

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Men/women, healthy human beings, age 18-70 years, BMI between 18.5 and 24.9 kg/m2, consistently stable body weight for at least 6 months (+/- 2 kg)

Exclusion criteria

Exclusion criteria: Type 2 diabetes mellitus (defined as fasting plasma glucose >= 7.0 mmol/L); Gastroenterological diseases or abdominal surgery (uncomplicated appendectomy, cholecystectomy and hysterectomy allowed, and other surgery upon judgment of the principle investigator); Cardiovascular diseases, cancer, liver or kidney malfunction, auto-immune diseases, disease with a life expectancy shorter than 5 years; Abuse of products; alcohol (>20 alcoholic consumptions per week) and drugs; Smoking; Plans to lose weight or following a hypocaloric diet; Use of any medication, including vitamin supplementation, except oral contraceptives, within 14 days prior to testing; Regular use of laxation products; Use of antibiotics in the 90 days prior to the start of study. Administration of investigational drugs or participation in any scientific intervention study which may interfere with this study (to be decided by the principle investigator), in the 90 days prior to the study; Known pregnancy, lactation (checked by a pregnancy test before start of study); Blood donation within 3 months before study period; Self-admitted HIV-positive state

Design outcomes

Primary

Measure	Time frame
The primary endpoint is the effect of five different protected pea protein extracts on intestinal satiety hormone release (CCK, GLP-1, PYY).	—

Secondary

Measure	Time frame
Secondary endpoint is the degradability of the different prototypes by human gastric fluid, tested in an in vitro setting.	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)